The End Gas Station Heroin Act classifies specific potent kratom alkaloids as Schedule I substances and establishes a framework to regulate and restrict the commercial distribution of emerging synthetic opioids.
Bernie Moreno
Senator
OH
The End Gas Station Heroin Act classifies specific potent kratom alkaloids (7-hydroxymitragynine and mitragynine pseudoindoxyl) as Schedule I controlled substances while providing an exemption for natural kratom products that meet strict concentration limits. Additionally, the bill establishes a framework to regulate and prohibit the commercial distribution of emerging synthetic opioids that pose significant health risks. Importantly, the legislation focuses enforcement efforts on manufacturers and distributors, explicitly protecting individuals from criminal or civil penalties for simple possession or personal use.
End Gas Station Heroin Act Sets Strict Limits on Kratom Extracts and Targets Synthetic Opioids in Commercial Markets
This bill takes a two-pronged approach to cleaning up the shelves at your local convenience store and smoke shop. First, it officially labels two potent compounds found in kratom—7-hydroxymitragynine (7OH) and mitragynine pseudoindoxyl—as Schedule I controlled substances, putting them in the same legal category as heroin. Second, it creates a broad net to catch 'emerging synthetic opioids' that haven't been specifically named in law yet, provided they are chemically made and more powerful than morphine. The goal is to stop the commercial sale of high-potency 'legal highs' while leaving room for standard, low-potency kratom products.
The Kratom Math
If you use kratom for focus or wellness, the fine print in Section 2 matters. The bill doesn't ban kratom entirely, but it sets a strict 'natural' ceiling. To stay legal, solid products like capsules or powders can’t have more than 1 milligram of 7OH per gram of product. For liquids, it’s 1 milligram per milliliter. Crucially, the bill also mandates a 1:100 ratio; you can't have more than one part of these potent compounds for every 100 parts of regular mitragynine. For a local shop owner, this means any 'extra strength' or 'super concentrated' extracts that are chemically spiked or heavily processed would suddenly become illegal to sell, while traditional leaf powder remains on the shelf.
Targeting the Sellers, Not the Users
One of the most interesting parts of this bill is how it handles the 'emerging' synthetics in Section 3. It gives the government the power to treat new, lab-made opioids as Schedule I substances the moment they hit the market, rather than waiting months for a specific law to pass. However, it draws a hard line at the checkout counter. The bill explicitly prohibits the government from criminally charging or suing someone solely for personal use or simple possession of these emerging synthetics. If you’re a construction worker who unknowingly bought a shady supplement for back pain, the law targets the distributor who put it in the store, not you. The focus is squarely on the 'commercial distribution'—the manufacturing, advertising, and selling for profit.
The Grey Areas of Potency
Because the bill targets substances based on how they affect the body rather than just their chemical name, there is some room for interpretation. Section 3 defines a 'covered emerging synthetic opioid' as anything that shows 'greater functional potency than morphine' based on 'scientifically reliable evidence.' While this helps law enforcement stay ahead of chemists who tweak a single molecule to bypass old laws, it creates a bit of a moving target. For manufacturers, this means the legality of a new product might depend on lab assays and Attorney General regulations that haven't been fully written yet. It’s a 'straight-shooting' attempt to stop the next wave of the opioid crisis, but it puts a lot of weight on how the government defines 'potency' in a lab setting.